Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

43.90
+1.533.61%
Post-market: 43.75-0.1500-0.34%18:52 EST
Volume:3.36M
Turnover:147.48M
Market Cap:11.77B
PE:18.47
High:44.20
Open:42.86
Low:42.75
Close:42.37
52wk High:49.62
52wk Low:32.38
Shares:268.11M
Float Shares:231.84M
Volume Ratio:1.12
T/O Rate:1.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.38
EPS(LYR):1.76
ROE:30.56%
ROA:17.73%
PB:5.45
PE(LYR):24.94

Loading ...

Earning Preview: Exelixis Q4 revenue is expected to increase by 7.19%, and institutional views are mostly positive

Earnings Agent
·
Feb 03

FDA NDA Move Puts Exelixis Colorectal Cancer Bet To The Test

Simply Wall St.
·
8 hours ago

Exelixis Is Maintained at Equal-Weight by Barclays

Dow Jones
·
Feb 04

Barclays Sticks to Its Hold Rating for Exelixis (EXEL)

TIPRANKS
·
Feb 04

Exelixis Price Target Maintained With a $52.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 03

Exelixis Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
Feb 03

Exelixis reports zanzalintinib new drug application accepted for review by FDA

TIPRANKS
·
Feb 02

FDA Accepts Exelixis Application for Zanzalintinib Combination in Metastatic Colorectal Cancer

Reuters
·
Feb 02

Exelixis Inc - FDA Sets Pdufa Target Action Date for December 3, 2026

THOMSON REUTERS
·
Feb 02

Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination With an Immune Checkpoint Inhibitor for Patients With Metastatic Colorectal Cancer

THOMSON REUTERS
·
Feb 02

Morgan Stanley Lifts Price Target on Exelixis to $49 From $48, Keeps Overweight Rating

MT Newswires Live
·
Feb 02

Exelixis Inc. to Release Fourth Quarter and Fiscal Year 2025 Financial Results

Reuters
·
Jan 28

Exelixis Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 27

Exelixis price target raised to $52 from $49 at H.C. Wainwright

TIPRANKS
·
Jan 27

Assessing Exelixis (EXEL) Valuation After Recent Share Price Pullback And Long Term Gains

Simply Wall St.
·
Jan 18

Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating

MT Newswires Live
·
Jan 14

Does Exelixis’ 2026 Revenue Guidance and Zanzalintinib Push Change The Bull Case For EXEL?

Simply Wall St.
·
Jan 14

Exelixis Projects 2026 Net Product Revenues of $2.325 Billion to $2.425 Billion

Reuters
·
Jan 13

Exelixis, Citigroup And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Benzinga_recent_news
·
Jan 12

Press Release: Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

Dow Jones
·
Jan 12